Marco Meglio

Data from the overall satralizumab treatment period, which expanded on the double-blind periods by adding new data from the ongoing open-label extension periods, were consistent with the double-blind period results.

Increases in physical, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other disease modifying therapies.

The Novartis agent showed benefit in patients who had multiple sclerosis both with and without relapses.

The Genentech agent, which is approved for patients with relapsing-remitting multiple sclerosis, showed no new safety signals in a comparison between conventional and shorter infusion times.

Plasma neurofilament light chain (pNfL) may serve as a prognostic tool to assess the risk of developing permanent disability in multiple sclerosis.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic detailed the need to incorporate interdisciplinary care and behavioral medicine in commonplace MS practice.

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

The data support the need to raise awareness of involuntary movements from possible tardive dyskinesia and the importance of properly screening and diagnosing patients.

The association between black individuals and processing speeds may explain the black-white disparities in dementia risk at older age.

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy.

Women with multiple sclerosis had a greater risk of macrovascular disease than men, which was consistent with previous studies.

During the COVID-19 pandemic, it is more important than ever to ensure that a patient with stroke is transferred to the right hospital the first time around.

The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.

Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.

System interventions could be used to modify patient behavior, leading to improved adherence and better clinical outcomes for those with sleep-disordered breathing, according to new data.

The FDA-approved treatment was associated with a clinically meaningful delay in needing continuous ventilation among patients with Duchenne muscular dystrophy.

Data suggest that discrepancies in genetic testing for epilepsy warrant second opinions for interpretations as well as clinical reports that become part of a patient’s medical record following a second opinion.

Women with migraine with cold extremities had higher attack frequencies, which data suggest stems partly from sleep disturbances.

The wide variance in onabotunlinumtoxinA use for migraine prevention raises the question of whether evidence-based advisory statements might be more helpful than a proscriptive protocol.

Treatment with SK Life Science’s cenobamate showed higher responder rates than placebo, regardless of baseline seizure frequency or disease duration.

The first study to assess the effect of endovascular therapy added on to intravenous thrombolysis uncovered more evidence of its effect on specific occlusions rather than overall outcomes.

Early treatment with Ionis Pharmaceuticals’s inotersen resulted in greater long-term disease stabilization than delayed initiation.

Data led the authors to believe that vitamin D might have neuroprotective properties and that levels may be a prognostic marker of long-term cognition and neuroaxonal integrity.

The exercise and physical activity recommendations were tailored to individuals with differing disability levels on the Expanded Disability Status Scale.

Treatment with fenfluramine was associated with greater seizure reduction, which in turn improved executive function over time in patients with Dravet syndrome.

Banner Life Science’s novel fumarate bioequivalent alternative to Tecfidera (dimethyl fumarate; Biogen) enters the market as a new oral treatment option for relapsing forms of multiple sclerosis.

An emphasis on at-home care as well as reducing the risk of seizure exacerbation are among a list of notable recommendations to help optimize clinical care for patients with epilepsy amidst the COVID-19 pandemic.

The FDA-approved anti-CGRP therapy from Eli Lilly demonstrated a significant ability to decrease monthly migraine days in patients who did not respond to previous medications.

The FDA-approved migraine therapy lasmiditan showed long-term efficacy and had similar change in Migraine Disability Assessment total score in both 100-mg and 200-mg doses.